Trials soon ready
Clinical trials expected to report results within the next 12 months, ranked by potential. Each trial shows its estimated finish date — explained in plain language.
Showing the top 50 of 32064 trials in this window.
-
Can a bone marrow trick make face transplants safer?
⭐️ CURE ⭐️ Recruiting nowBackground: The human face is critically important for breathing, eating, seeing, and speaking/ communicating, but its most important job may be to look like a human face. Devastating facial deformities often cause affected individuals to avoid human contact and disappear from so…
Results expected Aug 2026 (estimated)
Phase: PHASE2 • Sponsor: Johns Hopkins University • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
CRISPR stem cell therapy could end transfusions for sickle cell and thalassemia patients
Disease control Recruiting nowThis is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSP…
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
One-Time injection aims to restore hearing in children born deaf
⭐️ CURE ⭐️ OngoingThis study intends to assess safety, tolerability, and efficacy of SENS-501 in children between the ages of 6-31 months with pre-lingual hearing loss due to a mutation in the Otoferlin gene.
Results expected Jul 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Sensorion • Aim: ⭐️ CURE ⭐️
Last updated Jul 10, 2026 00:00 UTC
-
Can a One-Two punch of CAR-T and lenalidomide beat tough leukemia?
⭐️ CURE ⭐️ Recruiting nowThis is a Phase I/II interventional, open-label treatment study designed to evaluate the safety and efficacy of concomitant therapy with anti-CD19 CAR T-cells and Lenalidomide in adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) who have been pretreated w…
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Vitebsk Regional Clinical Cancer Centre • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Gene therapy breakthrough offers hope for rare brain disease
Disease control ENROLLING_BY_INVITATIONCanavan Disease is a congenital white matter disorder caused by mutations to the gene encoding for aspartoacylase (ASPA). Expression of ASPA is restricted to oligodendrocytes, the sole white matter producing lineage in the brain. ASPA supports myelination in the capacity of its s…
Results expected Aug 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Myrtelle Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThe overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (A…
Results expected Sep 2026 (estimated)
Phase: PHASE2, PHASE3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
One shot, six months of malaria shield? a new trial tests a powerful antibody in children
Prevention OngoingBackground and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and de…
Results expected Sep 2026 (estimated)
Phase: PHASE3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
⭐️ VACCINE ⭐️ OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: CanSino Biologics Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Aug 08, 2026 00:03 UTC
CanSino Biologics Inc. · 6185 HKEXReward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company ModerateA small company — one failure carries real weight.
-
Could a stem cell transplant cure immune diseases?
⭐️ CURE ⭐️ Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Reward if it works HighAn incremental result rather than a breakthrough.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
⭐️ CURE ⭐️ OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Dana-Farber Cancer Institute • Aim: ⭐️ CURE ⭐️
Last updated Jul 18, 2026 00:00 UTC
-
One-Time gene shot aims to stop bleeding in hemophilia a
Disease control Recruiting nowThis study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (…
Results expected Nov 2026 (estimated)
Phase: PHASE3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
⭐️ CURE ⭐️ Recruiting nowA study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose. Next, In dose expansion phase, patients were assign two…
Results expected Dec 2026 (estimated)
Phase: PHASE1 • Sponsor: Sichuan University • Aim: ⭐️ CURE ⭐️
Last updated Jul 23, 2026 00:00 UTC
-
One-Time gene fix could rescue 'Bubble Boy' disease
Disease control Recruiting nowThis is a Phase I/II trial of in vivo lentiviral gene therapy for treating adenosine deaminase severe combined immunodeficiency (ADA-SCID) using a self-inactivating lentiviral vector (LV) ivlv-ADA to functionally correct the genetic defect. The primary objectives are to evaluate …
Results expected Dec 2026 (estimated)
Phase: NA • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Hepatitis b cure breakthrough? new combo aims for 50%+ cure rate
⭐️ CURE ⭐️ Recruiting nowExploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overa…
Results expected Dec 2026 (estimated)
Phase: PHASE4 • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: ⭐️ CURE ⭐️
Last updated Jul 09, 2026 00:00 UTC
-
Bubble boy disease gene therapy trial launches
Disease control Recruiting nowThis is a Phase I/II gene therapy trial treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector (ivlv-X1) to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct intr…
Results expected Dec 2026 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Major RSV vaccine trial for seniors nears completion
⭐️ VACCINE ⭐️ OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase: PHASE3 • Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Thinking your way to movement: brain-computer interface tested for hand function in tetraplegia
Disease control Recruiting nowThis prospective, multicenter, single-arm clinical trial will enroll subjects with tetraplegia secondary to spinal cord injury. An implantable brain-computer interface system for compensatory hand motor function will be used to reconstruct upper-limb function, so as to evaluate t…
Results expected Jan 2027 (estimated)
Phase: NA • Sponsor: NeuroXess Technology (shanghai) Co.,Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can donor immune cells be engineered to fight blood cancer?
⭐️ CURE ⭐️ Recruiting nowKCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell malignancies.
Results expected Feb 2027 (estimated)
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Could ketamine be a fast-acting lifeline for suicidal teens and young adults?
Symptom relief Recruiting nowKetamine, an NMDA antagonist, has been shown to have rapid anti- suicidal effects. However, its safety and efficacy and special populations has not been investigated and documented. Several reports in adults suggest rapid decrease of suicidal ideation. In the last decade there is…
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: Tatiana Falcone, MD • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Can a single eye injection restore sight in genetic blindness?
⭐️ CURE ⭐️ OngoingThis is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 in patients with retinitis pigmentosa associated with NR2E3 and RHO mutations and in patients with LCA due to mutation(s) in CEP290 gene (OCU400-101). To document prospective eye pathology in the above subjects…
Results expected Mar 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Ocugen • Aim: ⭐️ CURE ⭐️
Last updated Aug 02, 2026 00:00 UTC
Ocugen · OCGN NASDAQ Trade on eToro (ad)Reward if it works Very highAiming at a cure or vaccine; success would transform the company.
Risk to the company HighA small company — one failure carries real weight.
-
Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
⭐️ CURE ⭐️ Recruiting nowThis is a prospective, single-arm phase II clinical trial intended to investigate the efficacy of neoadjuvant CTLA-4 monoclonal antibody combined with PD-1 monoclonal antibody plus preoperative chemoradiotherapy for locally advanced esophageal cancer. A total of 44 patients with …
Results expected Apr 2027 (estimated)
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Two-Drug combo aims to wipe out breast cancer before surgery in BRCA carriers
⭐️ CURE ⭐️ Recruiting nowThis study is an open-label, single-arm, multicenter clinical study. 64 patients with germline BRCA-mutated HER2-negative early breast cancer are planned to be enrolled and treated with fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of neoad…
Results expected Apr 2027 (estimated)
Phase: PHASE2 • Sponsor: Peking University People's Hospital • Aim: ⭐️ CURE ⭐️
Last updated Jul 23, 2026 00:00 UTC
-
Gene therapy trial aims to stop duchenne in its tracks
Disease control Recruiting nowThis is a multicenter, open-label, non-randomized study to investigate the safety, tolerability, and efficacy of a single intravenous (IV) infusion of SGT-003 in participants with Duchenne muscular dystrophy. There will be 5 cohorts in this study. Cohort 1 will include participan…
Results expected May 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: Solid Biosciences Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
Solid Biosciences Inc. · SLDB NASDAQ Trade on eToro (ad)Reward if it works Very highAn incremental result rather than a breakthrough.
Risk to the company HighA small company — one failure carries real weight.
-
Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
⭐️ CURE ⭐️ Recruiting nowThis phase I trial evaluates the best dose, possible benefits and/or side effects of fludarabine and cyclophosphamide with or without rituximab before CD19 chimeric antigen receptor T cells in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or h…
Results expected May 2027 (estimated)
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: ⭐️ CURE ⭐️
Last updated Jul 19, 2026 00:00 UTC
-
Can a gene therapy restore natural hearing after cochlear implants?
⭐️ CURE ⭐️ OngoingThis study will evaluate the safety, tolerability, and efficacy of EA0010 injection in patients with OTOF-related hearing loss who have already undergone cochlear implantation. Conventional gene therapy generally excludes cochlear implant recipients, based on the concern that the…
Results expected May 2027 (estimated)
Phase: NA • Sponsor: Shanghai EmayGene Technology Co., Ltd • Aim: ⭐️ CURE ⭐️
Last updated Aug 14, 2026 00:00 UTC
-
Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
Prevention Recruiting nowThe AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and…
Results expected Jun 2027 (estimated)
Sponsor: Clinton Health Access Initiative Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowDNA methylation changes occur early and broadly during carcinogenesis. Methylscape is a rapid assay that detects global DNA methylation patterns in body fluids (blood, urine, and saliva) and may detect a cancer signal and predict the cancer signal origin (CSO) from a single fluid…
Results expected Jun 2027 (estimated)
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
CRISPR stem cell therapy shows promise for kids with sickle cell
Disease control OngoingThis is a single-dose, open-label study in pediatric participants with severe SCD and hydroxyurea (HU) failure or intolerance. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Lab-Grown skin could transform burn healing
⭐️ CURE ⭐️ Recruiting nowThis multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in patients with deep partial and full-thickness burns as…
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: CUTISS AG • Aim: ⭐️ CURE ⭐️
Last updated Aug 12, 2026 00:00 UTC
-
Could this cell therapy free type 1 diabetes patients from insulin?
Disease control Recruiting nowThis study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Results expected Jun 2027 (estimated)
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Gene-Editing shot aims to halt rare nerve disease in phase 3 trial
Disease control Recruiting nowThis study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
Results expected Jul 2027 (estimated)
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
Intellia Therapeutics · NTLA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company ModerateA mid-sized company with other programmes alongside this one.
-
Can a single Gene-Editing injection stop a blinding corneal disease?
⭐️ CURE ⭐️ Not yet recruitingThe goal of this clinical trial is to evaluate the safety and efficacy of GEB-101 injection in subjects with TGFBI-related Corneal Dystrophy
Results expected Aug 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: GenEditBio Limited • Aim: ⭐️ CURE ⭐️
Last updated Aug 08, 2026 00:03 UTC
-
Ebola breakthrough? new trial aims to stop virus after exposure
Prevention Not yet recruitingEBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms. The trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD. Participants…
Results expected Aug 2027 (estimated)
Phase: PHASE3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Prevention
Last updated Jun 27, 2026 08:12 UTC
-
Can engineered immune cells tackle an incurable childhood brain tumor?
⭐️ CURE ⭐️ Recruiting nowThe CARMIGO Trial is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and young adults aged 2-16 years with Diffuse Midline Glioma (DMG). The study will evaluate the feasibility of gen…
Results expected Aug 2027 (estimated)
Phase: PHASE1 • Sponsor: University College, London • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a shot stop ALS before it starts? new trial tests tofersen in gene carriers
Disease control OngoingThe primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen a…
Results expected Aug 2027 (estimated)
Phase: PHASE3 • Sponsor: Biogen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
Biogen · BIIB NASDAQ Trade on eToro (ad)Reward if it works HighA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
-
Can a One-Time gene infusion rewrite the fate of PKU?
⭐️ CURE ⭐️ Recruiting nowThis is a Phase 1/2, open-label, multiple-center, dose escalation and cohort expansion study to evaluate the safety and efficacy of NGGT002 in adult subjects with classic Phenylketonuria (PKU). NGGT002 is a rAAV8 based vector carrying a functional copy of the human PAH gene. Par…
Results expected Aug 2027 (estimated)
Phase: PHASE1, PHASE2 • Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowStudy to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
Results expected Oct 2026 (estimated)
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Womb transplants could let infertile women give birth
Disease control OngoingThis study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries …
Results expected Nov 2026 (estimated)
Phase: NA • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
⭐️ CURE ⭐️ Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: New York Medical College • Aim: ⭐️ CURE ⭐️
Last updated Jul 29, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
⭐️ VACCINE ⭐️ OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 08, 2026 00:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
⭐️ CURE ⭐️ Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Engineered immune cells take on tough lymphomas
Disease control Recruiting nowDALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory B cell lymphoma (BCL). Cohorts include subjects with diffuse large B-cell lymp…
Results expected Dec 2026 (estimated)
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can whole blood beat component transfusions in trauma?
Disease control Recruiting nowThe goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who re…
Results expected Dec 2026 (estimated)
Phase: PHASE3 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Aiming to cure esophageal cancer without the knife
⭐️ CURE ⭐️ OngoingThe present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment o…
Results expected Jan 2027 (estimated)
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
New mRNA vaccine aims to stop the stomach flu
⭐️ VACCINE ⭐️ OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase: PHASE3 • Sponsor: ModernaTX, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Reward if it works Very highA late-stage readout — success would still be major news.
Risk to the company LowA large company running many trials — it absorbs a failure here.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to a broker we have a commercial relationship with, and we may earn a commission if you open an account. This never affects which trials are listed or how they are ranked.